세계의 대상포진 백신 시장(2026-2032년) : 제품 유형, 백신 유형, 유통 채널, 연령층, 지역별

Zoster Vaccine Market Valuation - 2026-2032

The rising prevalence of chronic diseases and the aging population are driving the demand for zoster vaccine market. Additionally, the zoster vaccine can be attributed to the increasing awareness regarding the importance of vaccination in helping to prevent shingles caused by the varicella-zoster virus is anticipated to fuel the market to surpass revenue of USD 1.62 Billion valued in 2024 and reach USD 3.47 Billion by 2032.

Also, growing advancements in vaccine technology and the development of new and more effective vaccines are also expected to propel the growth of the zoster vaccine market. The increasing implementation of healthcare policies in developed nations is enabling the market grow at a CAGR of about 10% from 2026 to 2032.

Zoster Vaccine Market: Definition/ Overview

The zoster vaccine, commonly referred to as the shingles vaccine, is a crucial preventive measure against herpes zoster, an ailment triggered by the reactivation of the varicella-zoster virus, which also causes chickenpox. This vaccine contains a weakened form of the virus, stimulating the immune system to produce antibodies that can prevent or mitigate the severity of shingles. Its primary application lies in preventing shingles in individuals aged 50 and older, who are at an increased risk due to age-related decline in immunity. Additionally, the vaccine helps in reducing complications associated with shingles, such as chronic pain and neurological issues.

Currently, there are two main types of zoster vaccines available that are Shingrix and Zostavax and future research is exploring even more effective options with broader applications. The Protection and require fewer doses, potential expansion of recommendations to include younger age groups or those with specific medical conditions, exploration of combination vaccines for simplified immunization schedules, and efforts to enhance global access, particularly in low- and middle-income countries, to alleviate the burden of shingles-related illness on a global scale.

Will Increasing Cases of Herpes Zoster Worldwide Drive the Growth of the Zoster Vaccine Market?

The prevalence of herpes zoster disease is rising globally due to factors such as the aging population, weakened immune systems, and increased prevalence of chronic diseases such as cancer and HIV will drive the growth of the zoster vaccine market

As a result, the demand for zoster vaccine is likely to increase in the coming years as more people become aware of the importance of vaccination to prevent shingles. This presents a significant opportunity for the growth of the zoster vaccine market. For instance, on 25 April 2023, GSK launched the shingles vaccine, (herpes zoster). GSK said the vaccine had 90% efficacy and provided at least 10 years of protection against herpes zoster.

The growing awareness among people about the importance of vaccination to prevent shingles is driving the demand for the zoster vaccine market. The aging population worldwide is also contributing to the growth of the market as older adults are more susceptible to shingles. For instance, according seroprevalence study in Indian subjects showed that by the age of 40 years, more than 90% of the participants had this virus in their bodies and were therefore vulnerable to shingles. For the prevention of shingles and post-herpetic neuralgia, Shingrix vaccine has been approved for adults above 50 years.

Furthermore, advancements in vaccine technology and the development of new and more effective vaccines are expected to boost the growth of the market. All these factors suggest that the zoster vaccine market is poised for steady growth in the coming years.

Will The High Cost of Zoster Vaccine Hamper the Growth of the Zoster Vaccine Market?

Increasing the high cost of the zoster vaccine can be a significant barrier for many people, especially in low-income countries, and it could potentially hamper the growth of the zoster vaccine market. This cost barrier stems from various factors, including the complexities of research and development, manufacturing processes, distribution logistics, and the necessity for multiple doses to ensure effective immunity.

Additionally, healthcare providers and institutions may face financial constraints in purchasing high-cost vaccines like the zoster vaccine, particularly in settings where reimbursement rates are inadequate. This can further limit access to vaccination and reduce overall demand, constraining market growth.

Growing awareness of stringent regulations can indeed pose a challenge to the growth of the zoster vaccine market. The regulatory approval process for vaccines can be lengthy and costly, which can delay the launch of new vaccines and limit their availability. Additionally, regulatory requirements for safety and efficacy can be strict, which can make it difficult for new manufacturers to enter the market.

Furthermore, the increasing occurrence of vaccine rashes can indeed hinder the growth of the zoster vaccine market. When people experience rashes or other adverse reactions after receiving a vaccine, it can lead to a decrease in confidence in the vaccine and reduce demand for it. This can ultimately impact the growth of the market.

Category-Wise Acumens

Will the Rising Utilization of the Shingrix Vaccine Drive the Zoster Vaccine Market?

The rising use of the Shingrix vaccine is expected to drive the zoster vaccine market. Shingrix is a highly effective vaccine for preventing zoster, and it has been shown to provide longer-lasting protection than other available vaccines. This vaccine provides a high level of immunity for at least 7 years after vaccination, as more people become aware of the benefits of Shingrix the demand for the vaccine is expected to increase, which will help to drive growth in the zoster vaccine market.

Additionally, during the forecast period, there will be a rise in demand for these vaccinations due to increasing awareness of the disease's effects and the growing number of countries that have approved Shingrix for use as a vaccine. For instance, GSK announced the shingles vaccine Shingrix in India. This vaccine is recommended for people aged 50 years and above to protect against shingles.

Increasing awareness of the importance of shingles vaccination will drive the zoster vaccine market Companies may invest in marketing efforts to differentiate their products and highlight their efficacy and safety profiles. Additionally, the drive for innovation may lead to the development of new vaccine formulations or delivery methods to better meet the needs of consumers.

The surge in demand for shingles vaccines propels market expansion, prompting vaccine manufacturers to bolster production capacities to satisfy healthcare providers and consumer requirements. This heightened production not only addresses immediate demand but also fosters increased investment in research and development. As revenue streams grow, manufacturers allocate more resources to R&D endeavors, aiming to enhance vaccine efficacy, safety, and accessibility

Increasing demand for technological developments in vaccine formulation, delivery, and production are improving the accessibility, safety, and efficacy of vaccinations. This accelerates the market's growth for zoster vaccines, providing better preventive treatments and enhanced public health results.

Will Increasing Demand for Recombinant Vaccine will Boost the Zoster Vaccine Market?

Recombinant vaccines are produced using genetic engineering techniques, which allows for more precise targeting of the virus or bacteria being targeted. This technology has been used to develop new vaccines, including the Shingrix vaccine for shingles. The growing use of recombinant vaccines offers several advantages over traditional vaccines, including improved safety, efficacy, and ease of production. As a result, they are becoming increasingly popular among healthcare providers and patients. This vaccine contains purified parts of pathogen that are antigenic, or necessary to elicit a protective immune response.

In addition to the benefits of recombinant vaccines, other factors such as the aging population, increasing healthcare expenditure, and rising awareness regarding the importance of preventive healthcare are expected to contribute to the growth of the zoster vaccine market. Aging comes with several health problems such as a weak immune system, which make the old population susceptible to infections like shingles. The increasing geriatric population globally estimated at 3 to 5 cases per 1000 individuals annually is contributing to the growth of the zoster vaccine market and is expected to continue its growth throughout the forecast period.

Country/Region-wise

How the Increasing Prevalence of Chickenpox in North America will Drive the Zoster Vaccine Market?

The rising prevalence of chickenpox in North America boost the zoster vaccine market. Chickenpox and shingles are caused by the same virus, known as the varicella-zoster virus. While chickenpox is a common childhood illness, the virus can remain dormant in the body and reactivate later in life as shingles. Additionally, recommendations for shingles vaccine may be part of the public health response to chickenpox outbreaks, especially for those who are more susceptible due to age or underlying medical issues. For Instance, on 7 September 2022, 21,060 cases of chickenpox were recorded by Mexican health authorities (11,057 males and 10,003 women). This is a significantly higher number than the 8,897 cases reported in 2021, a 137% rise. The likelihood of developing shingles is increased by the high prevalence of chickenpox.

The rising healthcare expenditure in North America has led to a surge in demand for the Zoster vaccine, thereby driving the growth of the market. This vaccine is highly effective in preventing shingles, which is a painful skin rash caused by the reactivation of the varicella-zoster virus.

Rising awareness regarding preventive healthcare will drive the zoster vaccine market. Public health campaigns and a growing focus on preventative measures are making people more aware of the importance of proactive healthcare. This shift in perspective is leading to a greater willingness to get vaccinated against diseases like shingles. People are becoming more informed about the potential complications of shingles, such as PHN, and understand the value of vaccination in preventing this debilitating condition. This growing awareness will likely lead to a significant increase in the demand for zoster vaccines in the coming years.

Will Growing Awareness of Government Vaccine Programs in Asia Pacific Drive the Zoster Vaccine Market?

Growing awareness of government vaccine programs in the Asia-Pacific region is expected to drive the demand for zoster vaccines and contribute to the growth of the market. Many governments in the region have launched vaccination programs to prevent various diseases, including shingles. These programs aim to increase awareness about vaccination and make vaccines more accessible to the population, especially older adults who are more susceptible to shingles.

For example, in Japan, the government has included the zoster vaccine in its national vaccination program for older adults, which covers the cost of the vaccine for eligible individuals. Additionally, in India, the government has launched various vaccination programs to prevent diseases such as hepatitis, influenza, and pneumococcal disease, which are also expected to increase awareness about the importance of vaccination and drive the demand for zoster vaccine.

Changing lifestyles in Asia-Pacific are expected to drive the zoster vaccine market. As people in the region become more health-conscious and adopt healthier lifestyles, the risk of developing shingles may decrease. However, the demand for zoster vaccine is still expected to increase as people become more aware of the importance of vaccination and take preventive measures to protect themselves against the disease.

Furthermore, government initiatives are expected to boost the growth of the market and encourage more manufacturers to invest in the development of new and more effective vaccines for shingles.

Competitive Landscape

The zoster vaccine market, while experiencing promising growth, is a concentrated landscape with a few key players vying for dominance. The zoster vaccine market is dynamic and competitive and will benefit public health. It can lead to the development of more effective, accessible, and affordable vaccines, offering broader protection against shingles and its debilitating complications. The interplay between established players, innovative newcomers, and regulatory bodies will define the future of the zoster vaccine market.

Some of the prominent players operating in the zoster vaccine market include:

• GSK plc
• Merck & Co., Inc.
• Curevo Inc
• Geneone Life Science
• SK bioscience

Latest Developments

• In February 2023, Pfizer Inc. and BioNTech SE launched a phase 1/2 trial to investigate the safety, tolerability, and immunogenicity of their mRNA vaccine candidates against varicella-zoster virus (VZV), which causes shingles, a severe condition referred to as herpes zoster, or HZ
• In April 2023, GSK launched an anti-shingles vaccine in India. The vaccine is used to prevent herpes zoster and neuralgia in adults aged 50 years old
• In February 2023, Jiangsu Recbio Technology Co., Ltd completed the first batch of subject enrollment for its adjuvant recombinant shingles vaccine, REC610.

Zoster Vaccine Market, By Category

• Product Type
• Zostavax
• Shingrix
• SKYZoster
• Vaccine Type:
• Recombinant Vaccine
• Live Attenuated Vaccine
• Distribution Channel:
• Hospital Pharmacy
• Retail Pharmacy
• Age Group:
• Above 50 to 65 Age
• Above 65 Age
• Above 18 to 50 Age
• Region:
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 MARKET DEFINITION
• 1.2 MARKET SEGMENTATION
• 1.3 RESEARCH TIMELINES
• 1.4 ASSUMPTIONS
• 1.5 LIMITATIONS

2 RESEARCH METHODOLOGY

• 2.1 DATA MINING
• 2.2 SECONDARY RESEARCH
• 2.3 PRIMARY RESEARCH
• 2.4 SUBJECT MATTER EXPERT ADVICE
• 2.5 QUALITY CHECK
• 2.6 FINAL REVIEW
• 2.7 DATA TRIANGULATION
• 2.8 BOTTOM-UP APPROACH
• 2.9 TOP-DOWN APPROACH
• 2.10 RESEARCH FLOW
• 2.11 THOUGHT LEADERSHIP OPINION

3 EXECUTIVE SUMMARY

• 3.1 GLOBAL ZOSTER VACCINE MARKET OVERVIEW
• 3.2 GLOBAL ZOSTER VACCINE MARKET ESTIMATES AND FORECAST (USD MILLION), 2024-2030
• 3.3 GLOBAL ZOSTER VACCINE MARKET VALUE (USD MILLION) ESTIMATES AND FORECAST, 2024-2030
• 3.4 GLOBAL ZOSTER VACCINE ECOLOGY MAPPING (% SHARE IN 2022)
• 3.5 COMPETITIVE ANALYSIS: FUNNEL DIAGRAM
• 3.6 GLOBAL ZOSTER VACCINE MARKET ABSOLUTE MARKET OPPORTUNITY
• 3.7 GLOBAL ZOSTER VACCINE MARKET ATTRACTIVENESS ANALYSIS, BY REGION
• 3.8 GLOBAL ZOSTER VACCINE MARKET ATTRACTIVENESS ANALYSIS, BY PRODUCT TYPE
• 3.9 GLOBAL ZOSTER VACCINE MARKET ATTRACTIVENESS ANALYSIS, BY VACCINE TYPE
• 3.10 GLOBAL ZOSTER VACCINE MARKET ATTRACTIVENESS ANALYSIS, BY AGE GROUP
• 3.11 GLOBAL ZOSTER VACCINE MARKET ATTRACTIVENESS ANALYSIS, BY SALES CHANNEL
• 3.12 GLOBAL ZOSTER VACCINE MARKET, BY PRODUCT TYPE (USD MILLION)
• 3.13 GLOBAL ZOSTER VACCINE MARKET, BY VACCINE TYPE (USD MILLION)
• 3.14 GLOBAL ZOSTER VACCINE MARKET, BY AGE GROUP (USD MILLION)
• 3.15 GLOBAL ZOSTER VACCINE MARKET, BY SALES CHANNEL (USD MILLION)
• 3.16 FUTURE MARKET OPPORTUNITIES

4 MARKET OUTLOOK

• 4.1 GLOBAL ZOSTER VACCINE MARKET EVOLUTION
• 4.2 GLOBAL ZOSTER VACCINE MARKET OUTLOOK
• 4.3 MARKET DRIVERS
  • 4.3.1 INCREASING PREVALENCE OF HERPES ZOSTER
  • 4.3.2 GROWING AWARENESS ABOUT HERPES ZOSTER
• 4.4 MARKET RESTRAINTS
  • 4.4.1 HIGH COST OF VACCINES
• 4.5 MARKET TRENDS
  • 4.5.1 AGEING POPULATION
• 4.6 MARKET OPPORTUNITY
  • 4.6.1 DEVELOPMENTS IN VACCINE TECHNOLOGY
• 4.7 PORTER'S FIVE FORCES ANALYSIS
  • 4.7.1 THREAT OF NEW ENTRANTS
  • 4.7.2 THREAT OF SUBSTITUTES
  • 4.7.3 BARGAINING POWER OF SUPPLIERS
  • 4.7.4 BARGAINING POWER OF BUYERS
  • 4.7.5 INTENSITY OF COMPETITIVE RIVALRY
• 4.8 MACROECONOMIC ANALYSIS
• 4.9 VALUE CHAIN ANALYSIS
• 4.10 PRICING ANALYSIS
• 4.11 REGULATIONS
  • 4.11.1 SAUDI FOOD AND DRUG AUTHORITY (SFDA)
• 4.12 PRODUCT LIFELINE

5 MARKET, BY PRODUCT TYPE

• 5.1 OVERVIEW
• 5.2 GLOBAL ZOSTER VACCINE MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY PRODUCT TYPE
• 5.3 ZOSTAVAX
• 5.4 SHINGRIX
• 5.5 SKYZOSTER

6 MARKET, BY VACCINE TYPE

• 6.1 OVERVIEW
• 6.2 GLOBAL ZOSTER VACCINE MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY VACCINE TYPE
• 6.1 LIVE ATTENUATED VACCINE
• 6.2 RECOMBINANT VACCINE

7 MARKET, BY SALES CHANNEL

• 7.1 OVERVIEW
• 7.2 GLOBAL ZOSTER VACCINE MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY SALES CHANNEL
• 7.3 PRIVATE
• 7.4 PUBLIC

8 MARKET, BY AGE GROUP

• 8.1 OVERVIEW
• 8.2 GLOBAL ZOSTER VACCINE MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY AGE GROUP
• 8.3 ABOVE 50 TO 65 AGE
• 8.4 ABOVE 65 AGE
• 8.5 ABOVE18 TO 50 AGE

9 MARKET, BY GEOGRAPHY

• 9.1 OVERVIEW
  • 9.1.1 INDIA
  • 9.1.2 TAIWAN
  • 9.1.3 THAILAND
  • 9.1.4 SAUDI ARABIA
  • 9.1.5 UAE
  • 9.1.6 TURKEY
  • 9.1.7 BRAZIL
  • 9.1.8 MEXICO
  • 9.1.9 ARGENTINA

10 COMPETITIVE LANDSCAPE

• 10.1 OVERVIEW
• 10.2 COMPETITIVE SCENARIO
• 10.3 COMPANY MARKET RANKING ANALYSIS
• 10.4 COMPANY REGIONAL FOOTPRINT
• 10.5 COMPANY INDUSTRY FOOTPRINT
• 10.6 ACE MATRIX
  • 10.6.1 ACTIVE
  • 10.6.2 CUTTING EDGE
  • 10.6.3 EMERGING
  • 10.6.4 INNOVATORS

11 COMPANY PROFILES

• 11.1 GLAXOSMITHKLINE PLC.
  • 11.1.1 COMPANY OVERVIEW
  • 11.1.2 COMPANY INSIGHTS
  • 11.1.3 SEGMENT BREAKDOWN
  • 11.1.4 PRODUCT BENCHMARKING
  • 11.1.5 KEY DEVELOPMENTS
  • 11.1.6 SWOT ANALYSIS
  • 11.1.7 WINNING IMPERATIVES
  • 11.1.8 CURRENT FOCUS & STRATEGIES
  • 11.1.9 THREAT FROM COMPETITION
• 11.2 MERCK & CO., INC.
  • 11.2.1 COMPANY OVERVIEW
  • 11.2.2 COMPANY INSIGHTS
  • 11.2.3 SEGMENT BREAKDOWN
  • 11.2.4 PRODUCT BENCHMARKING
  • 11.2.5 SWOT ANALYSIS
  • 11.2.6 WINNING IMPERATIVES
  • 11.2.7 CURRENT FOCUS & STRATEGIES
  • 11.2.8 THREAT FROM COMPETITION
• 11.3 SK BIOSCIENCES (SK CHEMICALS)
  • 11.3.1 COMPANY OVERVIEW
  • 11.3.2 COMPANY INSIGHTS
  • 11.3.3 PRODUCT BENCHMARKING
  • 11.3.4 SWOT ANALYSIS
  • 11.3.5 WINNING IMPERATIVES
  • 11.3.6 CURRENT FOCUS & STRATEGIES
  • 11.3.7 THREAT FROM COMPETITION
• 11.4 GENEONE LIFE SCIENCE
  • 11.4.1 COMPANY OVERVIEW
  • 11.4.2 COMPANY INSIGHTS
  • 11.4.3 PRODUCT BENCHMARKING
• 11.5 PFIZER
  • 11.5.1 COMPANY OVERVIEW
  • 11.5.2 COMPANY INSIGHTS
  • 11.5.3 SEGMENT BREAKDOWN
  • 11.5.4 PRODUCT BENCHMARKING
  • 11.5.5 KEY DEVELOPMENTS
• 11.6 CANSINO BIOLOGICS INC.
  • 11.6.1 COMPANY OVERVIEW
  • 11.6.2 COMPANY INSIGHTS
  • 11.6.3 SEGMENT BREAKDOWN
  • 11.6.4 PRODUCT BENCHMARKING
• 11.7 VACCITECH
  • 11.7.1 COMPANY OVERVIEW
  • 11.7.2 COMPANY INSIGHTS
  • 11.7.3 PRODUCT BENCHMARKING
  • 11.7.4 KEY DEVELOPMENTS
• 11.8 INOVIO PHARMACEUTICALS, INC.
  • 11.8.1 COMPANY OVERVIEW
  • 11.8.2 COMPANY INSIGHTS
  • 11.8.3 SEGMENT BREAKDOWN
• 11.9 CUREVO INC.
  • 11.9.1 COMPANY OVERVIEW
  • 11.9.2 COMPANY INSIGHTS
  • 11.9.3 PRODUCT BENCHMARKING